A Pfizer Inc. PFE vaccine designed to protect babies from respiratory syncytial virus, or RSV, got a green light Monday from the U.S. Food and Drug Administration — a key milestone for infant health as well as for the pharmaceutical giant’s future growth strategy.
The shot, which is administered to pregnant people for the protection of infants up to 6 months of age, is the first maternal RSV vaccine approved in the U.S., offering the potential to protect newborns from their first moments of life. RSV, which affects the lungs…
Read the full article here
